Free Access
Issue
J Extra Corpor Technol
Volume 37, Number 3, September 2005
Page(s) 319 - 323
DOI https://doi.org/10.1051/ject/200537319
Published online 15 September 2005
  1. Chong BH, Castaldi PA, Berndt MC. Thrombocytopenia: Effects of rabbit IgG, and its FAB and Fe fragments on antibody-heparin-phitelet interaction. Thrombosis Res. 1989;55:291–95. [CrossRef] [Google Scholar]
  2. King DJ, Kelton JG. Heparin associated thrombocytopenia. Ann Int Med. 1984;100:535–40. [CrossRef] [PubMed] [Google Scholar]
  3. Sodden R, Loebe M, Gorman KF, et al. Heparin-induced thrombocytopenia experiences in 12 heart surgery patients. ASAIO J. 1997;43:M430–M433. [CrossRef] [PubMed] [Google Scholar]
  4. Gallisti S, Muntean W. Heparin delays platelet aggregation in plasma more effectively than hirudin. Thromb Haemost. 1995;73;1453. [Google Scholar]
  5. Bove C, Casey B, Marder V. DDAVP reduces bleeding during continued hirudin administration in the rabbit. Thromb Haemost. 1995:73;1453. [Google Scholar]
  6. Summer S, Sheffield WA. Hirudin-albumin fusion protein retains characteristics of both components. Thromb Haemost. 1995:73:2105. [Google Scholar]
  7. Homberger W, Rubsamen K, Laux V, et al. New properties of an old antithrombotic: Long-acting hydrophobic hirudin derivatives with a high affinity to platelets and artificial surfaces. Thromb Haemost. 1995:73:2105. [Google Scholar]
  8. Potzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass—Assessment of the whole blood ecarin clotting time. Thromb Haemost. 199:77 920–25. [Google Scholar]
  9. Riess FC, Lower C, Seelig C, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man. J Thorac Cardiovasc Surg. 1995:110:265–67. [CrossRef] [Google Scholar]
  10. Riess FC, Potzsch B, Bader R, et al. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery. Eur J Cardiothorac Surg. 1996:10:386–88. [CrossRef] [Google Scholar]
  11. Koza MJ, Walenga JM, Fareed J, et al. A new approach in monitoring recombinant harudin during cardiopulmonary bypass. Semin Thromb Hemostasis. 1993:19:90–96. [Google Scholar]
  12. Nurmohamed MT, Berekmans R, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. Thromb Haemost 1994;72:685–92. [CrossRef] [PubMed] [Google Scholar]
  13. Hafner G, Fickenscher K, Friesen HJ, et al. Evaluation of an automated chromogenic substrate assay for the rapid determination of hirudin in plasma. Thromb Res. 1995;77:165–73. [CrossRef] [Google Scholar]
  14. Potzsch B, Greinacher A, Riess FC, et al. Recombinant hirudin as antieoagulant in cardiac surgery: Experiences with 11 patients. Ann Hematol. 1996;72:A4. [Google Scholar]
  15. Salmenpera M, Levy J, Harker L. Hemostasis and cardiopulmonary bypass. In: Mora C, Guylon R, Finlayson D, Rigatti R, eds. Cardiopulmonary Bypass Principles and Techniques of Extracorporeal Circulation. New York: Springer-Verlag: 1995: 92–93. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.